Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Free Report) (TSE:AUP) will post its 12/31/2023 quarterly earnings results before the market opens on Thursday, February 15th. Analysts expect Aurinia Pharmaceuticals to post earnings of ($0.18) per share for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.
Aurinia Pharmaceuticals Stock Performance
Aurinia Pharmaceuticals stock opened at $8.32 on Tuesday. The stock’s 50 day moving average price is $8.46 and its 200 day moving average price is $8.58. Aurinia Pharmaceuticals has a one year low of $6.94 and a one year high of $12.43. The company has a debt-to-equity ratio of 0.18, a quick ratio of 5.33 and a current ratio of 5.77. The firm has a market capitalization of $1.19 billion, a PE ratio of -15.70 and a beta of 1.46.
Hedge Funds Weigh In On Aurinia Pharmaceuticals
A number of institutional investors have recently added to or reduced their stakes in the company. Sunbelt Securities Inc. acquired a new position in shares of Aurinia Pharmaceuticals in the first quarter worth about $31,000. Geneos Wealth Management Inc. raised its position in shares of Aurinia Pharmaceuticals by 54.2% in the 1st quarter. Geneos Wealth Management Inc. now owns 3,250 shares of the biotechnology company’s stock valued at $40,000 after purchasing an additional 1,142 shares in the last quarter. AQR Capital Management LLC acquired a new position in shares of Aurinia Pharmaceuticals in the 4th quarter valued at approximately $52,000. Tower Research Capital LLC TRC raised its holdings in Aurinia Pharmaceuticals by 69.9% in the second quarter. Tower Research Capital LLC TRC now owns 6,390 shares of the biotechnology company’s stock valued at $62,000 after acquiring an additional 2,629 shares in the last quarter. Finally, Lazard Asset Management LLC raised its holdings in Aurinia Pharmaceuticals by 164.7% in the first quarter. Lazard Asset Management LLC now owns 5,300 shares of the biotechnology company’s stock valued at $65,000 after acquiring an additional 3,298 shares in the last quarter. Institutional investors and hedge funds own 39.64% of the company’s stock.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. The company also offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.
- Five stocks we like better than Aurinia Pharmaceuticals
- Compound Interest and Why It Matters When Investing
- 3 attractive stocks that insiders are buying
- What Does Downgrade Mean in Investing?
- Alpha and Omega Semiconductor ready to bounce, DOJ cloud lifts
- How to Invest in Apparel Stocks
- Wendy’s vs Shake Shack: Out with the new, in with the old?
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.